An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.
The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.
From The Independent. Ketamine-based treatments for severe depression could further fuel the addiction epidemic sweeping the US, researchers have warned, after a new study found the drug...